Sector News

Pfizer’s Upjohn to merge with Mylan

August 14, 2019
Life sciences

Generic pharmaceutical company Mylan will merge with Pfizer’s off-patent medicines unit Upjohn. The new firm will be based in the US, with anticipated revenues of $19–20 billion (£15–16 billion) in 2020.

The intention is to combine Pfizer’s distribution network in China and other emerging markets with Mylan’s existing products in developed markets and future generics, but the deal does not include Pfizer’s biosimilars.

‘Upjohn has off-patent drugs like Viagra (sildenafil), Lipitor (atorvastatin) and Lyrica (pregabalin), for which Mylan has filed generic applications. This makes me wonder what happens when there is overlap between Mylan’s generics and the branded Pfizer products,’ says Josh Whitehill, a lawyer specialising in pharmaceutical and biotechnology patent law at Goodwin Procter in New York, US. ‘Do they [sell them off], or does the new company just stop selling them?’ he asks.

‘It will be interesting to see if this starts a trend of large branded drug companies selling off or spinning off their off-patent assets,’ Whitehill says. Rather than a consolidation, the deal represents a shift of Upjohn into Mylan, he states. ‘I don’t see this as disrupting the status quo, it just really is giving Mylan more legs to reach places where it couldn’t before.’

By: Rebecca Trager

Source: Chemistry Week

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend